cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardiu

DOI: 10.1124/jpet.109.154468
Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 884-91.

#	Paper	IF	Citations
63	Controlling myocyte cGMP: phosphodiesterase 1 joins the fray. *Circulation Research*, **2009**, 105, 931-3	15.7	3
62	Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. *Journal of Cardiovascular Translational Research*, **2010**, 3, 507-15	3.3	38
61	The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. *Circulation Research*, **2010**, 107, 1164-6	15.7	13
60	Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 334, 1023-30	4.7	80
59	Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5646-51	11.5	84
58	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. *Pharmacological Reviews*, **2010**, 62, 525-63	22.5	677
57	Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. *Journal of the American College of Cardiology*, **2010**, 56, 2021-30	15.1	57
56	Phosphodiesterases as Drug Targets. *Handbook of Experimental Pharmacology*, **2011**,	3.2	20
55	PDE3 inhibition in dilated cardiomyopathy. *Current Opinion in Pharmacology*, **2011**, 11, 707-13	5.1	23
54	Phosphodiesterases and cardiac cGMP: evolving roles and controversies. *Trends in Pharmacological Sciences*, **2011**, 32, 360-5	13.2	73
53	Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. *Handbook of Experimental Pharmacology*, **2011**, 47-84	3.2	41
52	Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy. *Handbook of Experimental Pharmacology*, **2011**, 323-44	3.2	24
51	Phosphodiesterase inhibition in heart failure. *Handbook of Experimental Pharmacology*, **2011**, 237-49	3.2	27
50	Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models. *PLoS ONE*, **2011**, 6, e19922	3.7	9
49	Conserved expression and functions of PDE4 in rodent and human heart. *Basic Research in Cardiology*, **2011**, 106, 249-62	11.8	90
48	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. *Physiological Reviews*, **2011**, 91, 651-90	47.9	443
47	Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. *Hormone and Metabolic Research*, **2012**, 44, 766-75	3.1	22

46	Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model. *Thoracic and Cardiovascular Surgeon*, **2012**, 60, 247-54	1.6	2
45	Differential expression of PDE5 in failing and nonfailing human myocardium. *Circulation: Heart Failure*, **2012**, 5, 79-86	7.6	60
44	Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells. *Antioxidants and Redox Signaling*, **2012**, 17, 460-70	8.4	52
43	Phosphodiesterase-5 and retargeting of subcellular cGMP signaling during pathological hypertrophy. *Circulation*, **2012**, 126, 916-9	16.7	6
42	Phosphodiesterases and cyclic GMP regulation in heart muscle. *Physiology*, **2012**, 27, 248-58	9.8	38
41	Cyclic GMP-dependent signaling in cardiac myocytes. *Circulation Journal*, **2012**, 76, 1819-25	2.9	82
40	Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. *Journal of Molecular and Cellular Cardiology*, **2012**, 52, 330-40	5.8	76
39	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. *Journal of the American College of Cardiology*, **2012**, 59, 1921-7	15.1	58
38	Nitric oxide synthase in post-ischaemic remodelling: new pathways and mechanisms. *Cardiovascular Research*, **2012**, 94, 304-15	9.9	15
37	Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 19778-83	11.5	20
36	Sildenafil prevents the up-regulation of transient receptor potential canonical channels in the development of cardiomyocyte hypertrophy. *Biochemical and Biophysical Research Communications*, **2013**, 436, 514-8	3.4	14
35	Therapeutic potential of PDE modulation in treating heart disease. *Future Medicinal Chemistry*, **2013**, 5, 1607-20	4.1	24
34	Synthesis, docking studies, pharmacological activity and toxicity of a novel pyrazole derivative (LQFM 021)--possible effects on phosphodiesterase. *Chemical and Pharmaceutical Bulletin*, **2013**, 61, 524-31	1.9	16
33	Signaling effectors underlying pathologic growth and remodeling of the heart. *Journal of Clinical Investigation*, **2013**, 123, 37-45	15.9	307
32	Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. *PLoS ONE*, **2013**, 8, e58841	3.7	22
31	By targeting Stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion. *Cellular Physiology and Biochemistry*, **2014**, 34, 955-65	3.9	62
30	Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2014**, 387, 407-17	3.4	15
29	Exercise training in adverse cardiac remodeling. *Pflugers Archiv European Journal of Physiology*, **2014**, 466, 1079-91	4.6	7

28	Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. *Trends in Pharmacological Sciences*, **2014**, 35, 404-13	13.2	45
27	New pharmacologic interventions to increase cardiac contractility: challenges and opportunities. *Current Opinion in Cardiology*, **2015**, 30, 285-91	2.1	10
26	The emperor's new clothes: PDE5 and the heart. *PLoS ONE*, **2015**, 10, e0118664	3.7	26
25	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. *Archives of Toxicology*, **2015**, 89, 1401-38	5.8	337
24	Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. *Circulation: Heart Failure*, **2015**, 8, 57-63	7.6	32
23	Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis. *Clinical Immunology*, **2015**, 161, 333-8	9	9
22	Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2015**, 308, H1575-82	5.2	16
21	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. *Pharmacology & Therapeutics*, **2015**, 147, 12-21	13.9	144
20	Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy. *JACC Basic To Translational Science*, **2016**, 1, 235-250	8.7	16
19	Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 284-92	4.7	13
18	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. *Journal of Endocrinological Investigation*, **2016**, 39, 131-42	5.2	18
17	Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. *Canadian Journal of Physiology and Pharmacology*, **2017**, 95, 295-304	2.4	7
16	Signalling Microdomains: The Beta-3 Adrenergic Receptor/NOS Signalosome. *Cardiac and Vascular Biology*, **2017**, 215-244	0.2	
15	A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	11
14	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. *British Journal of Pharmacology*, **2018**, 175, 223-231	8.6	21
13	Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro. *Circulation: Heart Failure*, **2018**, 11, e004571	7.6	23
12	HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half. *Mayo Clinic Proceedings*, **2018**, 93, 1305-1314	6.4	20
11	Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E7428-E7437	11.5	24

10	Phosphodiesterase expression in the normal and failing heart. *Archives of Biochemistry and Biophysics*, **2019**, 662, 160-168	4.1	11
9	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. *Journal of Cardiovascular Pharmacology*, **2020**, 75, 370-384	3.1	8
8	Multi-Compartment, Early Disruption of cGMP and cAMP Signalling in Cardiac Myocytes from the Model of Duchenne Muscular Dystrophy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
7	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. *Endocrines*, **2020**, 1, 90-101	0.8	2
6	cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype. *Journal of Cardiovascular Pharmacology*, **2020**, 75, 516-525	3.1	6
5	Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. *Cardiovascular Drugs and Therapy*, **2020**, 34, 401-417	3.9	7
4	An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases. *Expert Opinion on Drug Discovery*, **2021**, 16, 183-196	6.2	3
3	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. *Meditsinskiy Sovet*, **2019**, 192-202	0.4	
2	Heart Failure. **2020**, 529-544		
1	Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. **2022**, 15, 1024		